Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H9DB
|
||||
| Former ID |
DNC005964
|
||||
| Drug Name |
8-biphenyl-2-yl-2-morpholin-4-ylchromen-4-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H21NO3
|
||||
| Canonical SMILES |
C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4C5=CC=CC=C<br />5
|
||||
| InChI |
1S/C25H21NO3/c27-23-17-24(26-13-15-28-16-14-26)29-25-21(11-6-12-22(23)25)20-10-5-4-9-19(20)18-7-2-1-3-8-18/h1-12,17H,13-16H2
|
||||
| InChIKey |
VKLCRMQPVMPSKE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | DNA-dependent protein kinase catalytic subunit | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Non-homologous end-joining | ||||
| Cell cycle | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| Pathway Interaction Database | DNA-PK pathway in nonhomologous end joining | ||||
| Coregulation of Androgen receptor activity | |||||
| Class I PI3K signaling events mediated by Akt | |||||
| BARD1 signaling events | |||||
| Reactome | Nonhomologous End-Joining (NHEJ) | ||||
| WikiPathways | DNA Damage Response | ||||
| Non-homologous end joining | |||||
| FAS pathway and Stress induction of HSP regulation | |||||
| Cytosolic sensors of pathogen-associated DNA | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Prostate Cancer | |||||
| Double-Strand Break Repair | |||||
| Cell Cycle | |||||
| miRNA Regulation of DNA Damage Response | |||||
| References | |||||
| REF 1 | J Med Chem. 2005 Dec 1;48(24):7829-46.Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.